Sensitivity to Cisplatin in Glioma Cells and EGR-1 Expression
Author Information
Author(s): Calogero Antonella, Porcellini Antonio, Lombari Vincenza, Fabbiano Cinzia, Arcella Antonietta, Miscusi Massimo, Ponti Donatella, Ragona Giuseppe
Primary Institution: Department of Medical-surgical Science and Biotechnologies, University of Rome 'Sapienza'
Hypothesis
Does the expression of EGR-1 predict sensitivity to cisplatin in glioma cells?
Conclusion
Higher levels of EGR-1 expression in glioma cells are associated with reduced sensitivity to cisplatin.
Supporting Evidence
- EGR-1 expression correlates significantly with sensitivity to cisplatin.
- Lower EGR-1 levels in glioma cells are linked to higher drug sensitivity.
- Six out of 18 cell lines had mutations in the p53 gene or p16/INK4a/ARF gene complex.
Takeaway
The study found that glioma cells with lower EGR-1 levels are more sensitive to a cancer drug called cisplatin.
Methodology
Cytotoxicity assays were performed on primary cell lines derived from fresh tumor explants of 18 human cases of malignant glioma.
Potential Biases
Potential bias due to the limited number of cell lines and the specific genetic backgrounds of the tumors.
Limitations
The study is limited to a small sample size of 18 cell lines and may not represent all glioma types.
Participant Demographics
Eighteen human cases of malignant glioma were used to derive the primary cell lines.
Statistical Information
P-Value
p=0.0009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website